



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

**Public Declaration of Interests and Confidentiality Undertaking of
European Medicines Agency (EMA),
Scientific Committee members and experts**

Public declaration of interests

I, **Björg Bolstad**

Organisation/Company: Norwegian Medicines Agency

Country: Norway

do hereby declare on my honour that, to the best of my knowledge, the only direct or indirect interests I have in the pharmaceutical industry are those listed below:

2.1 Employment

Period	Company	Category	Products	Therapeutic Indication
01/2011-09/2015	Nordic Nanovector ASA	Executive role	Chief Clinical Officer (2011 to 2014); Senior Director Clinical Development (1 January 2015 to 14 September 2015)	
01/2006-12/2010	Algeta ASA	Executive role	Director Clinical Development	
02/2003-12/2005	Algeta ASA	Lead role	Alpharadin (Xofigo)	Treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease
09/1989-08/1999	Nycomed Imaging AS	Lead role	Visipaque	Iodinated x-ray contrast agent for intravascular administration
			NC100100	Ultrasound contrast agent for intravascular administration
09/1999-01/2003	PhotoCure ASA	Lead role	Metvix cream	Treatment of thin or non-hyperkeratotic and non-pigmented actinic keratoses on the face and scalp when other therapies are considered less appropriate. Only for treatment of superficial and/or nodular basal cell carcinoma unsuitable for other available therapies due to possible treatment related morbidity and poor cosmetic outcome; such as lesions on the mid-face or ears, lesions on

				<p>severely sun damaged skin, large lesions, or recurrent lesions.</p> <p>Treatment of squamous cell carcinoma in situ (Bowen's disease) when surgical excision is considered less appropriate.</p>
--	--	--	--	---

2.2 Consultancy

No interest declared

2.3 Strategic advisory role

No interest declared

2.4 Financial interests

No interest declared

2.5 Principal investigator

No interest declared

2.6 Investigator

No Interest Declared

2.7 Grant / Funding to organisation /institution

No interest declared

2.8 Close family member interest

No interest declared

2.9 Any other interests or facts

I have had shares in Nordic Nanovector ASA until 6 July 2015.

CONFIDENTIALITY UNDERTAKING

In view of the following definitions:

"EMA Activities" encompass any meeting (including meeting preparation and follow-up, associated discussion or

any other related activity) of the European Medicines Agency's Management Board, Committees, Working Parties, Expert Groups, or any other such meeting; work as an expert on assessments; work as an expert on guidance development.

"Confidential Information" means all information, facts, data and any other matters of which I acquire knowledge, either directly or indirectly, as a result of my EMA Activities.

"Confidential Documents" mean all drafts, preparatory information, documents and any other material, together with any information contained therein, to which I have access, either directly or indirectly, as a result of my participation in EMA Activities. Furthermore, any records or notes made by me relating to Confidential Information or Confidential Documents shall be treated as Confidential Documents.

I understand that I may be invited to participate either directly or indirectly in certain EMA activities and hereby undertake:

- To treat all Confidential Information and Confidential Documents under conditions of strict confidentiality.
- Not to disclose (or authorise any other person to disclose) in any way to any third party any Confidential Information or Confidential Document.
- Not to use (or authorise any other person to use) any Confidential Information or Confidential Document other than for the purposes of my work in connection with EMA activities.
- To dispose of Confidential Documents as confidential material as soon as I have no further use for them.

This undertaking shall not be limited in time, but shall not apply to any document or information that I can reasonably prove was known to me before the date of this undertaking or which becomes public knowledge other than as a result of a breach of any of the above undertakings.

I confirm the information declared on this form is accurate to the best of my knowledge and I acknowledge that my information will be stored electronically and published on the EMA website.

Full Name:	Björg Bolstad/ 9 May 2019
Date:	2019-05-09

For Definitions of activities etc, refer to Policy on Handling of Conflicts of Interest / Electronic DOI template